{
  "specimenId": "astrazeneca",
  "scannedDate": "2026-02-15",
  "claimsFound": 8,
  "quality": "rich",
  "searchesCompleted": 5,
  "urlsFetched": 6,
  "searchFailures": [],
  "fetchFailures": ["https://www.astrazeneca.com/media-centre/press-releases/2026/full-year-q4-2025-results.html"],
  "claims": [
    {
      "id": "astrazeneca--001",
      "specimenId": "astrazeneca",
      "claimType": "utopian",
      "secondaryType": null,
      "text": "Healthcare is undergoing a transformation, driven by data, computing power and smart techniques such as AI.",
      "speaker": "Pascal Soriot",
      "speakerTitle": "CEO",
      "context": "Homerton College lecture titled 'What Science Can Do', discussing digital transformation of healthcare industry",
      "rhetoricalFunction": "Frames AI as part of epochal industry transformation, positioning AstraZeneca within a historic shift in healthcare",
      "source": "Cambridge Independent",
      "sourceUrl": "https://www.cambridgeindependent.co.uk/business/astrazeneca-ceo-pascal-soriot-heralds-new-era-of-collaboration-in-homerton-college-lecture-9053114/",
      "sourceType": "Speech",
      "sourceDate": "2019",
      "collectedDate": "2026-02-15",
      "transcriptSource": false,
      "taxonomyFlag": null,
      "notes": ""
    },
    {
      "id": "astrazeneca--002",
      "specimenId": "astrazeneca",
      "claimType": "teleological",
      "secondaryType": null,
      "text": "Our ultimate goal is to improve the lives of people. By developing new treatments for people suffering from diseases that cannot be cured today, by creating great jobs through economic development.",
      "speaker": "Pascal Soriot",
      "speakerTitle": "CEO",
      "context": "Homerton College lecture on AstraZeneca's mission and innovation strategy",
      "rhetoricalFunction": "Anchors AI and innovation work in specific falsifiable moral outcomes: curing disease and creating jobs",
      "source": "Cambridge Independent",
      "sourceUrl": "https://www.cambridgeindependent.co.uk/business/astrazeneca-ceo-pascal-soriot-heralds-new-era-of-collaboration-in-homerton-college-lecture-9053114/",
      "sourceType": "Speech",
      "sourceDate": "2019",
      "collectedDate": "2026-02-15",
      "transcriptSource": false,
      "taxonomyFlag": null,
      "notes": ""
    },
    {
      "id": "astrazeneca--003",
      "specimenId": "astrazeneca",
      "claimType": "identity",
      "secondaryType": null,
      "text": "We want to collaborate, operate in a porous environment where ideas can be shared.",
      "speaker": "Pascal Soriot",
      "speakerTitle": "CEO",
      "context": "Homerton College lecture discussing AstraZeneca's open innovation approach",
      "rhetoricalFunction": "Defines organizational character as open, collaborative, permeable to external ideas",
      "source": "Cambridge Independent",
      "sourceUrl": "https://www.cambridgeindependent.co.uk/business/astrazeneca-ceo-pascal-soriot-heralds-new-era-of-collaboration-in-homerton-college-lecture-9053114/",
      "sourceType": "Speech",
      "sourceDate": "2019",
      "collectedDate": "2026-02-15",
      "transcriptSource": false,
      "taxonomyFlag": null,
      "notes": ""
    },
    {
      "id": "astrazeneca--004",
      "specimenId": "astrazeneca",
      "claimType": "teleological",
      "secondaryType": null,
      "text": "If you want to help patients treat their diseases better, if you want to also save money overall from the healthcare, I think you're willing to integrate digital technologies and pharmaceuticals that will help you diagnose diseases better.",
      "speaker": "Pascal Soriot",
      "speakerTitle": "Global CEO",
      "context": "CGTN BizTalk interview on AI integration in pharmaceutical industry",
      "rhetoricalFunction": "Links AI adoption to specific patient outcomes and healthcare cost reduction",
      "source": "CGTN BizTalk",
      "sourceUrl": "https://news.cgtn.com/news/2019-10-25/BizTalk-AstraZeneca-s-CEO-shares-insights-on-future-of-healthcare-L5a8TweYus/index.html",
      "sourceType": "Interview",
      "sourceDate": "2019-10-25",
      "collectedDate": "2026-02-15",
      "transcriptSource": false,
      "taxonomyFlag": null,
      "notes": ""
    },
    {
      "id": "astrazeneca--005",
      "specimenId": "astrazeneca",
      "claimType": "survival",
      "secondaryType": null,
      "text": "Europe is losing ground. They're focused more on social benefits and managing costs. It's like one company is trying to drive the top line, creating opportunities and economic growth, while another company is trying to manage costs and staying flat on the top line. That doesn't work.",
      "speaker": "Pascal Soriot",
      "speakerTitle": "CEO",
      "context": "Fortune interview explaining AstraZeneca's $2.5 billion US investment and why Europe is falling behind in innovation",
      "rhetoricalFunction": "Frames European status quo as unviable, justifying strategic shift toward US innovation ecosystem",
      "source": "Fortune",
      "sourceUrl": "https://fortune.com/2025/07/22/astrazeneca-ceo-pascal-soriot-building-us-europe/",
      "sourceType": "Interview",
      "sourceDate": "2025-07-22",
      "collectedDate": "2026-02-15",
      "transcriptSource": false,
      "taxonomyFlag": null,
      "notes": "While not explicitly about AI, this survival-framing justifies AstraZeneca's shift to US where AI/innovation ecosystem is stronger"
    },
    {
      "id": "astrazeneca--006",
      "specimenId": "astrazeneca",
      "claimType": "higher-calling",
      "secondaryType": null,
      "text": "We are very optimistic about what AI and digital transformation can do. But we also need to be vigilant and ensure that we harness these technologies ethically and responsibly.",
      "speaker": "Pascal Soriot",
      "speakerTitle": "CEO",
      "context": "Investment Reports interview on AI adoption philosophy at AstraZeneca",
      "rhetoricalFunction": "Frames ethical responsibility as overriding commercial enthusiasm for AI",
      "source": "Investment Reports",
      "sourceUrl": "https://www.investmentreports.co/interview/pascal-soriot-994",
      "sourceType": "Interview",
      "sourceDate": "2024",
      "collectedDate": "2026-02-15",
      "transcriptSource": false,
      "taxonomyFlag": null,
      "notes": "Pre-existing specimen quote elevated to purpose claim"
    },
    {
      "id": "astrazeneca--007",
      "specimenId": "astrazeneca",
      "claimType": "teleological",
      "secondaryType": null,
      "text": "These advances are accelerating innovative science and the delivery of life-changing medicines.",
      "speaker": "Pascal Soriot",
      "speakerTitle": "CEO",
      "context": "Investment Reports interview on AI impact in drug development",
      "rhetoricalFunction": "Links AI capabilities to specific outcome of delivering life-changing medicines faster",
      "source": "Investment Reports",
      "sourceUrl": "https://www.investmentreports.co/interview/pascal-soriot-994",
      "sourceType": "Interview",
      "sourceDate": "2024",
      "collectedDate": "2026-02-15",
      "transcriptSource": false,
      "taxonomyFlag": null,
      "notes": "Pre-existing specimen quote elevated to purpose claim"
    },
    {
      "id": "astrazeneca--008",
      "specimenId": "astrazeneca",
      "claimType": "identity",
      "secondaryType": null,
      "text": "There is no central group that determines what projects we will or won't do.",
      "speaker": "Brian Dummann",
      "speakerTitle": "Chief Data Officer",
      "context": "CDO Magazine interview on AstraZeneca's decentralized AI governance model",
      "rhetoricalFunction": "Defines AstraZeneca's identity as decentralized, autonomous, non-hierarchical in AI adoption",
      "source": "CDO Magazine",
      "sourceUrl": "https://www.cdomagazine.tech/aiml/inside-astrazenecas-ai-strategy-cdo-brian-dummann-on-innovation-governance-and-speed",
      "sourceType": "Interview",
      "sourceDate": "2024",
      "collectedDate": "2026-02-15",
      "transcriptSource": false,
      "taxonomyFlag": null,
      "notes": "Pre-existing specimen quote elevated to purpose claim; speaks to organizational character"
    }
  ]
}
